Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
100.27
-0.40 (-0.40%)
At close: Nov 13, 2026, 4:00 PM EST
99.48
-0.79 (-0.79%)
After-hours: Nov 13, 2026, 7:56 PM EST
Halozyme Therapeutics Employees
Halozyme Therapeutics had 423 employees as of December 31, 2025. The number of employees increased by 73 or 20.86% compared to the previous year. That makes Halozyme Therapeutics the 21,339th largest employer in the world and 2,798th in the United States.
Employees
423
Change (1Y)
73
Growth (1Y)
20.86%
Revenue / Employee
$4,261,106
Profits / Employee
$1,147,565
Market Cap
11.43B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 423 | 73 | 20.86% |
| Dec 31, 2024 | 350 | -23 | -6.17% |
| Dec 31, 2023 | 373 | -20 | -5.09% |
| Dec 31, 2022 | 393 | 248 | 171.03% |
| Dec 31, 2021 | 145 | 9 | 6.62% |
| Dec 31, 2020 | 136 | 4 | 3.03% |
| Dec 31, 2019 | 132 | -149 | -53.02% |
| Dec 31, 2018 | 281 | 26 | 10.20% |
| Dec 31, 2017 | 255 | -4 | -1.54% |
| Dec 31, 2016 | 259 | 43 | 19.91% |
| Dec 31, 2015 | 216 | 63 | 41.18% |
| Dec 31, 2014 | 153 | -17 | -10.00% |
| Dec 31, 2013 | 170 | 18 | 11.84% |
| Dec 31, 2012 | 152 | 17 | 12.59% |
| Dec 31, 2011 | 135 | 33 | 32.35% |
| Dec 31, 2010 | 102 | -38 | -27.14% |
| Dec 31, 2009 | 140 | 10 | 7.69% |
| Dec 31, 2008 | 130 | 38 | 41.30% |
| Dec 31, 2007 | 92 | 52 | 130.00% |
| Dec 31, 2006 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,000 |
| Madrigal Pharmaceuticals | 915 |
| Vaxcyte | 507 |
| TG Therapeutics | 399 |
| Krystal Biotech | 295 |
| Kymera Therapeutics | 285 |
| Summit Therapeutics | 265 |
HALO News
- 2 days ago - Morgan Stanley downgrades Halozyme to Equal Weight on valuation - TheFly
- 3 days ago - Halozyme downgraded to Equal Weight from Overweight at Morgan Stanley - TheFly
- 7 days ago - Halozyme share selloff an attractive buying opportunity, says H.C. Wainwright - TheFly
- 7 days ago - Halozyme says Enhanze technology in J&J’s Rybrevant Faspro - TheFly
- 7 days ago - Halozyme sees ‘zero to minimal’ royalty revenue impact to 2035 from CMS rule - TheFly
- 7 days ago - Leerink downgraded Halozyme to Market Perform on limited upside potential - TheFly
- 7 days ago - Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029 - PRNewsWire
- 7 days ago - Halozyme downgraded to Market Perform from Outperform at Leerink - TheFly